Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

580
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.3K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

544
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
544

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a risk score for transthyretin amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: the GRECA-TAVI registry.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2026
Same author

Publisher Correction: QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Medicine shapes ethics; however, it has to be the other way round as well.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2026
Same author

Temporal Expression of NLRP3 Inflammasome Components in Patients with Acute Coronary Syndrome.

Life (Basel, Switzerland)·2026
Same author

Sex and gender differences in coronary pathophysiology and ischaemic heart disease.

European heart journal·2026
Same author

Imaging and Quantification of Perivascular Adipose Tissue.

Arteriosclerosis, thrombosis, and vascular biology·2026

Related Experiment Video

Updated: Apr 3, 2026

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.4K

Intercellular communication lessons in heart failure.

Claudia Bang1, Charalambos Antoniades2, Alexios S Antonopoulos2

  • 1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany.

European Journal of Heart Failure
|September 24, 2015
PubMed
Summary
This summary is machine-generated.

Emerging communication networks, including vesicle exchange and molecular crosstalk between organs, are crucial in heart failure progression. Understanding these intercellular signals offers new therapeutic targets for cardiovascular diseases.

Keywords:
Heart failurecell-cell communicationinter-organ communicationparacrine signalling mediators

More Related Videos

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells
10:46

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Published on: July 16, 2013

16.8K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K

Related Experiment Videos

Last Updated: Apr 3, 2026

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

8.4K
Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells
10:46

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Published on: July 16, 2013

16.8K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K

Area of Science:

  • Cardiovascular Biology
  • Cellular Communication
  • Pathophysiology

Background:

  • Cell-cell and inter-organ communication are vital for homeostasis and organ function.
  • Heart failure involves complex cellular and molecular changes, impacting cardiomyocytes and fibroblasts.
  • Existing knowledge on intercellular signaling in heart failure is expanding beyond direct interactions.

Purpose of the Study:

  • To review emerging intercellular communication networks in heart failure pathogenesis.
  • To elucidate the underlying mechanisms of these novel communication pathways.
  • To identify potential therapeutic targets for cardiovascular disease drug development.

Main Methods:

  • Literature review of recent studies on intercellular communication in heart failure.
  • Analysis of mechanisms involving vesicle exchange, lipid crosstalk, and paracrine signaling.
  • Synthesis of findings related to heart, kidney, and adipose tissue interactions.

Main Results:

  • Dynamic interactions between diverse cell types are critical in heart failure.
  • Intercellular communication involves direct contact, paracrine mediators, and vesicle-mediated genetic exchange.
  • Crosstalk between the heart and distant organs like the kidney and adipose tissue contributes to disease progression.

Conclusions:

  • Emerging communication networks significantly influence cardiovascular disease conditions.
  • Novel therapeutic strategies can be developed by targeting these intercellular communication pathways.
  • Understanding these complex interactions is key to advancing heart failure treatment.